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In recent years the statistical mechanics of non-spherical molecules, such as polypeptide chains and protein
molecules, has garnered considerable attention as their phase behavior has important scientific and health im-
plications. One example is provided by immunoglobulin, which has a “Y”-shape. In this work, we determine
the phase diagram of Y-shaped molecules on a hexagonal lattice through Monte Carlo Grand Canonical ensem-
ble simulation, using histogram reweighting, multicanonical sampling, and finite-size scaling. We show that
(as expected) this model is a member of the Ising universality class. For low temperatures, we implemented
multicanonical sampling to induce faster phase transitions in the simulation. By studying several system sizes,
we use finite-size scaling to determine the two phase coexistence curve, including the bulk critical temperature,
critical chemical potential, and critical density.
I. INTRODUCTION
Our immune system is our primary defense against
pathogenic organisms and malignant cells. A major compo-
nent of this system is the class of proteins known collectively
as immunoglobulin G (IgG). These are multidomain proteins
that are particularly important due to their ability to bind to
antigens with remarkable specificity. Antibodies have many
practical applications due to this unusual specificity: this in-
cludes a large number of diagnostic applications in vitro, such
as immunofluorescence, western blotting, and enzyme-linked
immunosorbent assay analysis[1]. Antibodies have also
become of intense interest in the pharmaceutical world, due
to their efficacy as therapeutic molecules. This is evidenced
by the large number of antibodies that are either approved,
or in clinical trials for treating human disorders such as
cancer, rheumatoid arthritis, osteoporosis, and asthma[2–4].
In such situations, highly concentrated antibody solutions are
required in order to have therapeutic effect. However, such
high concentration solutions present important stability and
delivery challenges, such as aggregation and large solution
viscosity. A large value of the viscosity occurs for IgG2,
for example, at concentrations of 150 mg/ml, apparently
due to a transition of the solution to a gel[5]. Therefore,
understanding the condensation of proteins in solutions of
highly concentrated immunoglobulin is of importance in
pharmaceutical applications.
IgG molecules have a characteristic Y-shape, with two
distal Fab arms that bind selectively to particular antigens.
All of them have the same size and Y-conformation, due to
their common genetic basis. However, they differ in their
specific sequence of amino acids in the variable domains of
the Fab arms. As noted by Wang et al. [6], the variability
in the amino acid sequences can produce a large increase
in the overall attractive interactions between neighboring
IgG molecules. As a consequence, these interactions can
cause a variety of phase transitions, including reversible
aggregation, liquid-liquid phase separation, crystallization,
and gelation, which occur in a wide variety of proteins[7–9].
Although IgGs are typically quite soluble at physiological
conditions, sometimes they can become insoluble. In fact,
recent studies of protein condensation have been published
both for recombinant pharmaceutical IgGs and monoclonal
IgGs[10–17]. A detailed discussion of the importance of IgGs
in physiological and pharmaceutical situations is given by
Wang et al.[6], as well as Nezlin[18]. Wang et al. stress that
systematic studies of the phase behavior and phase diagrams
of IgG solutions are crucial for the understanding of the
pathological condensation in humans, as well as the stability
of antibody drug formulations.
Of particular interest to this paper are the experimental
studies of liquid-liquid phase transitions by Benedek et al
[6, 11, 17]. They have reported several important results in a
recent study of liquid-liquid phase separation in eight human
myeloma IgGs and two recombinant pharmaceutical human
IgGs. The first thing to note is that all liquid-liquid coexis-
tence curves have quite similar shapes. These curves differ
from those found for quasi-spherical proteins in that they
are broad and asymmetric and have relatively small critical
concentrations. The similarity of their shapes is presumably
due to their common Y-shape. The critical temperatures of
these liquid-liquid phase separations vary from one IgG to
another, due to the variability in the amino acid sequences that
leads to different net attractive protein-protein interactions.
These transitions are also metastable and are preempted by
the stable fluid-solid(freezing) transition, with the transition
temperatures typically in the range of −20◦C to −30◦C. The
study of such phase transitions is a relatively new, but rapidly
emerging research area. It is therefore of interest to examine
the effects of such an unusual architecture on model studies
of phase transitions. One such study has already been carried
out on a model of IgG[19].
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2In this paper we present an initial study of Y-shaped molecules
by focusing on such molecules on two-dimensional lattices.
Although this model might lack some important features of
the phase transitions undergone by IgG in three dimensions
(for example, it does not yield any notable asymmetry in
the phase diagram), it does provide an example of a phase
transition of a molecule with an unusual architecture. In
addition, there are examples of IgG on two dimensional
surfaces. For example, human IgG has been adsorbed to bio-
material surfaces, which can enhance long-term macrophage
adhesion in vitro[20]. (However , in that case the Y molecules
are not aligned only in the plane, but have some alignment
perpendicular to the plane, in contrast to our model.) Due to
the geometry of the molecule, we choose to use hexagonal
lattices on which the Y-molecules can be naturally placed.
To study the possible phase transition of our model, we
use grand-canonical Monte Carlo simulations along with
the usual histogram reweighting and multicanonical biasing
methods. The outline of our paper is as follows: In Section II
we define our model and the method by which we study it.
In Section III we present our results, namely that this model
belongs to the Ising universality class. This particular result
was expected a priori since the order parameter is a scalar.
Using finite-size scaling (FSS) methods, we also obtain the
liquid-liquid phase separation curve, including the location
of the critical point in the thermodynamic limit. We also
provide results for the finite-size system critical point, using
a standard scaling analysis. In Section IV we present a brief
conclusion.
II. MODEL AND SIMULATION
Our model of the Y-shaped molecule is implemented within
the environment of a two-dimensional hexagonal lattice with
side length L containing L2 sites. Periodic boundary con-
ditions are employed. Each of the N molecules occupies 4
lattice sites; the four include one central site and 3 rigid distal
arms. This leads to a maximum number density of the system
ρ of 0.25. The interactions included in this study are those be-
tween distal arms, and their respective nearest-neighbor dis-
tal arms, as shown in Fig.1, each with interaction strength
of J . For simplicity, there are no center-to-center, center-
to-distal arm, or any lattice binding energies. The total en-
ergy of the system U is then the summation of all distal arm-
distal arm interactions. We execute grand-canonical Monte
Carlo (GCMC) simulations. To analyze the data and obtain
the phase diagram, we use the Bruce-Wilding finite-size scal-
ing (FSS) techniques[21, 22], along with histogram reweight-
ing and multicanonical sampling methods[23], to compile the
phase diagram of this system. The fact that the order parame-
ter for this model (defined below) is a scalar suggests that this
Y-molecule model belongs to the Ising universality class, as
we show in Section III.
Assuming that our model belongs to the Ising universality
class, the critical point of our system can be determined by
matching the probability density function (PDF) of the order-
FIG. 1: Each center ( ) and arm ( ) occupy one lattice site,
and each arm is physically bonded to the center(—). The
interactions between arms and their nearest neighbors are
denoted by←→.
ing operator M of our system with the universal distribution
of the two-dimensional Ising class. The order parameter M
for the fluid is given by[21, 22]
M =
1
1− sr [ρ− su], (1)
where u = U/N is the energy density, and s and r are system
specific parameters to be determined later. Similar to the order
parameter M , the energy-like parameter ε is given by
ε = 1
1− sr [u− rρ]. (2)
The Ising universality class has two relevant scaling fields,
namely h, the ordering scaling field, and τ , the thermal scaling
field. For fluids in this universality class, τ and h are defined
as
τ = ωc − ω + s(µ− µc), h = µ− µc + r(ωc − ω), (3)
where ω = J/kT , µ is the reduced chemical potential in units
of kT , and the subscript c denotes the critical point. The pa-
rameters r and s determine the degree of mixing in the relative
scaling fields as well as M and ε.
During a simulation in a system size of side L, at fixed
values of µ and ω, we record the molecule number density
ρ and the energy density u, from which we determine the
joint probability density function P (ρ, u). The joint PDF,
P (M,ε), for the rescaled variables,M and ε, is related to the
joint distribution of density and energy such that P (M,ε) =
(1 − sr)P (ρ, u). We focus mostly on the order parameter
PDF P (M) =
∫
dεP (M,ε). At the critical point, all mem-
bers of the Ising universality class have the same fixed point
distribution function. In the simulations, this fixed point dis-
tribution and the PDF of our model are expressed as P˜M (x)
and PL(M) respectively, where x = α−1M L
β/ν(M − Mc).
β = 1/8 and ν = 1 are the critical exponents of the or-
der parameter and correlation length of the two-dimensional
Ising class, respectively. α−1M is a scaling parameter such that
P˜M (x) has unit variance. Therefore, the PDF PL(x) of our
model must also match P˜M (x) at the fixed point. It is only for
3large L that the numerically obtained PDF tends to the fixed
point distribution P˜M (x).
The fixed point function P˜M (x) for the two-dimensional
Ising model has been determined from previous work [21].
For one system size, by varying T , µ, and s, and matching
the numerically obtained PL(x) with P˜M (x), we can deter-
mine the Tc(L), µc(L), and ρc(L) of our model at said sys-
tem size. By repeating this process for multiple system sizes,
the bulk critical temperature(Tc), chemical potential(µc), and
density(ρc) can be extrapolated. We obtain the parameter r
from the slope of the µ-ω coexistence line at criticality[22] as
seen in Fig.2.
To avoid performing numerous simulations, we use the
standard method of histogram reweighting. To analyze the
data and obtain the phase diagram, we use the Bruce-Wilding
FSS techniques outlined here[21, 22, 24, 25]. In order to
obtain the critical parameters of the infinite system, we per-
formed GCMC simulations for systems with side lengths 30,
40, 50, and 60 with periodic boundary conditions. The ob-
servables recorded during the simulation were u and ρ, from
which, P (ρ, u), P (ρ), P (M, ε), and others were calculated.
For each temperature, chemical potential, and system size, the
simulation ran for 5,000 - 6,000 Monte Carlo steps (MCS),
and for 15,000 - 25,000 Monte Carlo steps for simulations im-
plementing and not implementing biasing techniques respec-
tively, before recording the density and energy of the system.
Each MCS comprises N attempts to change the system either
by a molecule translation, rotation, insertion, or removal. The
changes that the GCMC attempts to make to the system are
defined as follows:
Translation: Attempt to move the center of a randomly se-
lected molecule to one of the 6 nearest neighboring sites
of the center.
Rotation: Attempt to rotate a randomly selected molecule
either clockwise, or counter-clockwise about the
molecule center.
Insertion: Attempt to place a molecule, with a random orien-
tation, on a randomly chosen lattice site.
Removal: Attempt to remove a randomly selected molecule.
This algorithm is ergodic. The density and energy of the sys-
tem are recorded a total of 150,000 - 250,000 times over the
length of the simulation, with 1,000 - 2,000 and 2,000 - 4,000
MCS in between each recording for systems with and without
the preweighting function, respectively.
III. RESULTS
The method we use to find the bulk critical parameters is
as follows. First, we plot PL(x) for varying system sizes and
find best fits to the universal fixed point P˜M (x) by varying
Tc(L), µc(L), and s. A sample best fit of PL(x) to this fixed
point is shown in Fig.3 and shows that, within the accuracy of
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FIG. 2: Plot of reduced chemical potential µ versus the
reduced interaction strength ω. The parameter r is the slope
of this curve at the critical temperature and is found to be
r = −6.111.
our study, our model belongs to the Ising universality class.
Next, we use the FSS predictions[24] that
Tc − Tc(L) ∝ L−(θ+1)/ν (4)
and
µc − µc(L) ∝ L−(θ+1)/ν (5)
to determine the bulk values of the critical temperature and
critical chemical potential. In these equations, Tc and µc are
the actual bulk critical temperature and chemical potential,
and Tc(L) and µc(L) are the apparent bulk critical tempera-
ture and chemical potential determined from matching PL(x)
to the fixed universal distribution P˜M (x). θ is a correction to
scaling exponent. We use the value θ = 1.35, as calculated by
Barma and Fisher[26], which coincides with the conjecture
of Nienhuis[27] for the two-dimensional Ising system. The
next step is to record Tc(L) and µc(L) for each system size,
plot Tc(L) and µc(L) versus L−(θ+1)/ν , and then extrapo-
late to the infinite system size for both Tc(L) and µc(L). We
then record the extrapolated points as Tc and µc. The result-
ing graphs of Tc(L) and µc(L) versus L−(θ+1)/ν are given in
Fig.4.
FSS also predicts a similar correction to the critical density
of the model, namely
ρc − ρc(L) ∝ L−(d−1/ν), (6)
where ρc is the bulk critical density, ρc(L) is the apparent
critical density of a system of size L at Tc and µc, and d = 2
is the dimensionality of the system. Similar to the cases of
Tc and µc, ρc is extrapolated from the plot in Fig.5 and is
ρc = 0.127± 0.002.
The coexistence curve was determined through a series of
GCMC simulations at varying temperatures below the critical
region, implementing the histogram reweighting and multi-
canonical sampling techniques discussed previously. Coex-
istence between two phases at a temperature T is confirmed
when the areas underneath the two peaks in the density dis-
tribution P (ρ) are equal. The peak densities are recorded and
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FIG. 3: PL(x) (◦) for L = 60 and the universal fixed point
distribution P˜M (x)(–) versus x. Tc(L) and µc(L) were
Tc(L) = 1.084 and µc(L) = −6.477. Reproduced by
permission of IOP Publishing, N. B. Wilding, and A. D.
Bruce, “Density fluctuations and field mixing in the critical
fluid” Phy.: Condens Matter 4, 3087-3108 (1992). Copyright
1992 by IOP Publishing. All rights reserved[22].
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(a) Apparent Tc(L) vs L−(θ+1)/ν
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FIG. 4: a.) Plot of apparent bulk critical temperature
determined from matching PL(x) to P˜M (x). b.) Plot of the
apparent bulk critical chemical potential determined from
matching PL(x) to P˜M (x). The extrapolated critical
temperature and chemical potential are Tc = 1.081± 0.002
and µc = −6.66± 0.01.
plotted on the phase diagram. Examples of some density dis-
tributions for varying T at coexistence are shown in Fig.6.
In temperature regions apart from the critical region, finite-
size effects are expected to be negligible since the correlation
length is much smaller than that of the size of the system. With
this expectation, the density peaks of P (ρ) found in our finite
systems at different temperatures below the critical region will
still mimic that of an infinitely large system. A phase diagram
of the infinite system is constructed by determining the posi-
tions of the peaks in P (ρ) for sub-critical temperatures. As an
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FIG. 5: Plot of the apparent ρc(L) vs L−1/ν . The
extrapolated ρc = 0.127± 0.002.
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FIG. 6: Plot of estimated P (ρ) versus ρ for varying
temperatures at coexistence. All P (ρ) were determined as
described in the text.
additional check on this estimate of the equilibrium densities,
we also calculate the average density of each the two phases
present by using the PDFs to calculate these statistical aver-
ages. Our results are shown in Fig.7, where the FSS estimates
of Tc and ρc are also plotted.
We fit the points of our phase diagram to a power law of the
form[24]
ρ± ρc = a|T − Tc| ± b|T − Tc|β . (7)
This fit is also included in Fig.7. There is a small asym-
metry evident on the high density side of the phase diagram,
but not as pronounced as the one found experimentally or nu-
merically in 3D for IgG. We show the critical parameters de-
termined through the FSS method in Table I. We also show
in Fig.8 a typical configuration of a high density system in
equilibrium.
r s Tc µc ρc
−6.111 ' 0.05 1.081± 0.002 −6.66± 0.01 0.127± 0.002
TABLE I: List of all critical point parameters
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FIG. 7: The reduced temperature versus density, as obtained
by the two methods discussed in the text. The values
obtained from the positions of the maxima of the probability
distribution functions ( ) and from the average values ()are
plotted as a function of temperature. Also shown is the best
fit to data through Tc and ρc of the form
ρ± ρc = a|T − Tc| ± b|T − Tc|β with a = 0.05 and
b = 1.65.
FIG. 8: Sample of system size L = 30, at number density
ρ = 0.2156 and temperature T = 1.08.
IV. CONCLUSION
We end this paper with a few comments. First, the major
feature of our work is that we have determined in detail
using finite-size scaling methods the phase diagram of a
molecule with unusual architecture. We have chosen a very
simple model for the interaction between these molecules;
it would be straightforward to include other interactions in
future work. We have shown that the model belongs to the
Ising universality class as one might expect, since its order
parameter is a scalar. It seems clear that future research will
increasingly deal with unusual molecular architectures. We
note in passing the fact that the molecule has a Y-shape has
not resulted in an asymmetry of the type found for IgG on the
high density side. There are several reasons for this. First,
our model is two-dimensional. Second, we have not taken
into account in the model the large excluded volume effect
that characterizes IgG, which Bendek et al. [6] have argued is
responsible for its asymmetry. Indeed, the three-dimensional
model of IgG studied by Li et al. [19] does have an excluded
volume effect, and the phase diagram shows a pronounced
asymmetry similar to that observed in experiment. It should
also be noted that the reason our model has an asymmetry is
due to the absence of a particle-hole symmetry, such as that
present in the Ising model.
One direction for future research is to improve our model
in order to describe the absorption of IgG on surfaces[19].
The inclusion of surfaces would require a somewhat more
complex simulation algorithm, but would have the benefit of
producing richer phase behavior. Another research direction
would involve a more chemistry based, coarse-grained model
of IgG, such as the one proposed by Voth’s group [28], to
study not only its phase transitions, but its viscosity. Such
models are especially useful in probing the electrostatic
interaction between antibodies and its impact on ordering.
Finally, we note that the rheological information (such as the
viscosity) that could be obtained with a coarse-grained model
is of considerable interest in the pharmaceutical world.
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